Marshall R Posner

6PUBLICATIONS
78CO-AUTHORS
Predictive and prognostic markersTumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 19, 2026
Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.

|Mar 21, 2026
Development of Glioblastoma Multiforme in Patients With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma: A Case Series.

Jessica T Lovett, Michael Wotman, Ryan Denu

|Sep 08, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.

Caroline Even, Kevin J Harrington, Erminia Massarelli

|Mar 17, 2025
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.

Mansi Saxena, Thomas U Marron, Julia Kodysh

|Aug 11, 2023
Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance.

Glenn J Hanna, Scott A Roof, Jamie Jabalee

|May 16, 2022
Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma.

Barry M Berger, Glenn J Hanna, Marshall R Posner

Pageof 1

Frequent Collaborators

2 joint publications

Kevin J Harrington

2 joint publications

Krzysztof J Misiukiewicz

2 joint publications

Catherine Del Vecchio Fitz

2 joint publications

Eric M Genden